First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055

Menopause

Volumn 13, Issue 4, 2006, Pages 678-691

  Rauš, Karel ^a   Brucker, Cosima ^b   Gorkow, Christoph ^c   Wuttke, Wolfgang ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Nuremberg Clinic Centre   (Germany)

^c Bionorica AG   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Black cohosh; CR BNO 1055; Liver; Safety study; Uterus

Indexed keywords

CIMICIFUGA RACEMOSA EXTRACT; CR BNO 1055; PLANT EXTRACT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CALCULATION; CELL PROLIFERATION; CIMICIFUGA RACEMOSA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; OPEN STUDY; PROSPECTIVE STUDY; STATISTICS; SYMPTOM; TREATMENT DURATION;

ADMINISTRATION, ORAL; BLOOD PRESSURE; BODY WEIGHT; BONE DENSITY; CIMICIFUGA; CZECH REPUBLIC; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; FEMALE; GERMANY; HEART RATE; HUMANS; MAMMARY GLANDS, HUMAN; MIDDLE AGED; PHYTOESTROGENS; PLANT EXTRACTS; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 33746056433     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000196813.34247.e2     Document Type: Article

References (40)

1. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994;29:319-336.
2. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005;23:117-125.
3. Tataryn IV, Meldrum DR, Lu KH, Frumar AM, Judd HL. LH, FSH and skin temperature during the menopausal hot flash. J Clin Endocrinol Metab 1979;49:152-154.
4. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-1218.
5. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-S316.
6. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
8. Alving B. NIH asks participants in Women's Health Initiative Estrogen-Alone Study to stop study pills, begin follow-up phase. 2004. Available at: http://www.nih.gov/news/pr/mar2004/nhlbi-02.htm. Accessed August 3, 2005.
9. Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004;82:145-148, quiz 265.
10. Liske E, Wüstenberg P. Therapy of climacteric complaints with Cimicifuga racemosa: a herbal medicine with clinically proven evidence. Presented at the 9th Annual Meeting of The North American Menopause Society. Toronto, Canada, 1998.
11. Stoll W. Phytomedicine influences atrophic vaginal epithelium: double-blind study of cimicifuga versus estrogenic substance. Therapeuticon 1987;1:23-31.
12. Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003;44(Suppl 1):S67-S77.
13. Liske E, Hanggi W, Henneicke-von Zepelin HH, Boblitz N, Wustenberg P, Rahlfs VW. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002;11:163-174.
14. Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005;105:1074-1083.
15. Wuttke W, Jarry H, Becker T, et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? Maturitas 2003;44(Suppl 1):S9-S20.
16. Hagels H, Baumert-Krauss J, Freudenstein J. Composition of phenolic constituents in Cimicifuga racemosa. Presented at the International Congress and 48th Annual Meeting of the Society for Medicinal Plant Research. Zürich, 2000.
17. Struck D, Tegtmeier M, Harnischfeger G. Flavones in extracts of Cimicifuga racemosa. Planta Med 1997;63:289-290.
18. McCoy J, Kelly W. Survey of Cimicifuga racemosa for phytoestrogenic flavonoids. In: Society AC, ed. 212th American Chemical Society National Meeting. Orlando, FL, 1996.
19. Jarry H, Harnischfeger G, Düker E. The endocrine effects of constituents of Cimicifuga racemosa 2. In vitro binding of constituents to estrogen receptor. German Planta Med 1985;4:316-319.
20. Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats. Maturitas 1996;25:149-153.
21. Burdette JE, Liu J, Chen SN, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem 2003;51:5661-5670.
22. Jarry H, Metten M, Spengler B, Christoffel V, Wuttke W. In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas 2003;44(Suppl 1):S31-S38.
23. Gardiner SA, Morrison MF, Mozley PD, et al. Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women. Am J Geriatr Psychiatry 2004;12:621-630.
24. European Agency for the Evaluation of Medicinal Products. Points to Consider on Hormone Replacement Therapy. London: Committee for Proprietary Medical Products, 1997.
25. European Agency for the Evaluation of Medicinal Products. EAftEoMP. ICH Topic E 6 Guideline for Good Clinical Practice, Note for Guidance on Good Clinical Practice. London: Committee for Proprietary Medicinal Products, 1997.
26. WMA. Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects, 48th World Medical Association General Assembly. Somerset West, Republic of South Africa, October 1996.
27. Kurman RJ, Mazur MT. Endometrial polyps. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. Berlin, Heidelberg, New York: Springer-Verlag, 1987:305-307.
28. Cornier E. The Pipelle: a disposable device for endometrial biopsy. Am J Obstet Gynecol 1984;148:109-110.
29. Wolfe JN. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 1976;37:2486-2492.
30. American College of Radiology. ACoR. Breast Imaging Reporting and Data System (BI-RADS™). Third. Reston, VA, 1998.
31. Potthoff P, Heinemann LA, Schneider HP, Rosemeier HP, Hauser GA. The Menopause Rating Scale (MRS II): methodological standardization in the German population Lin German. Zentralbl Gynakol 2000;122:280-286.
32. Hartung J. Statistik 13. München: Oldenbourg Verlag, 2002:202ff.
33. Kuhl HT, Dysfunktionelle Blutungen HD. In: Kuhl HT, ed. Statistik HD. Das Klimakterium. Stuttgart, New York: Georg Thieme Verlag, 1987:207-210.
34. Schulz KD, Albert US, Bock K, Duda VF, Hadji P. Einfluss der Hormone Replacement Therapy (HRT) auf die bildgebende Diagnostik. J Menopause 2001;2:22-26.
35. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-722.
36. Kaufman Z, Garstin WI, Hayes R, Michell MJ, Baum M. The mammographic parenchymal patterns of women on hormonal replacement therapy. Clin Radiol 1991;43:389-392.
37. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
38. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-675.
39. Soska V. Poruchy metabolizmu lipidu: diagnostika a lécba. Praha: Grada, 2001:166.
40. Seidlova-Wuttke D, Jarry H, Becker T, Christoffel V, Wuttke W. Pharmacology of Cimicifuga racemosa extract BNO 1055 in rats: bone, fat and uterus. Maturitas 2003;44(Suppl 1):S39-S50.